X-ZELL among Asia's 20 most innovative health-tech start-ups Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL as one of the 20 most innovative health technology...
Ground-breaking X-ZELL research featured in BJU International Oxford, August 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-associated Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate cancer....
Applications for global Cryoimmunostaining™ technology trial now open Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, atypical cell detection specialist X-ZELL is now making the company’s patented...
X-ZELL CEO to present at Asia-Pacific Prostate Cancer Conference Brisbane, July 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, will use the upcoming Asia-Pacific Prostate Cancer Conference (APCC) in Brisbane next month as a platform to reveal “exciting new insights” into...
National University Hospital Singapore and X-ZELL sign LOI Singapore, June 2018 – The Department of Urology at Singapore’s National University Hospital and X-ZELL have signed a Letter of Intent (LOI) to jointly conduct a prospective, blinded study evaluating the...
X-ZELL breaks new ground for fluorescence microscopy Basel, June 2018 – Dr Sebastian Bhakdi, CEO of cancer detection start-up X-ZELL Inc., has outlined a ground-breaking new microscopy technique in the June edition of Methods & Protocols. In a bid to make the...
